Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.41 |
| ▸ | ORAI2 | Q96SN7 | 3/20 | 0.41 |
| ▸ | ORAI3 | Q9BRQ5 | 3/20 | 0.41 |
| ▸ | TRPV6 | Q9H1D0 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | THRB | P10828 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL9784059 | 0.97 | ORAI1 (0.39) | ORAI1ORAI2ORAI3TRPV6TSHR | |
| SCHEMBL23219858 | 0.72 | TRPV6 (0.50) | ORAI1ORAI2ORAI3TRPV6TSHR | |
| SCHEMBL3886199 | 0.71 | LMNA (0.50) | ORAI1ORAI2ORAI3TRPV6TSHR | |
| SCHEMBL17682412 | 0.67 | ORAI1 (0.38) | ORAI1ORAI2ORAI3TRPV6TSHR | |
| SCHEMBL4558373 | 0.65 | ALDH1A1 (0.36) | ORAI1ORAI2ORAI3TRPV6TSHR | |
| SCHEMBL3955823 | 0.65 | ORAI1 (0.40) | ORAI1ORAI2ORAI3TRPV6TSHR | |
| SCHEMBL9777193 | 0.65 | ALDH1A1 (0.36) | ORAI1ORAI2ORAI3TRPV6TSHR | |
| Allylamine SCHEMBL6678252 | 0.64 | ALDH1A1 (0.43) | ORAI1ORAI2ORAI3TRPV6TSHR | |
| SCHEMBL125450 | 0.63 | TRPV6 (0.53) | ORAI1ORAI2ORAI3TRPV6TSHR | |
| SCHEMBL991201 | 0.60 | TRPV6 (0.50) | ORAI1ORAI2ORAI3TRPV6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861359-B1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-2399743-A2 | Resin composition for laser engraving, relief printing plate precursor for laser engraving and process for producing same, and process for making relief printing plate | Fujifilm Corporation (JP) | 2011-12-28 | — | — | EP | disclosed |
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | HANAZAWA TAKESHI | 2011-06-23 | — | — | US | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1866278-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1861359-A1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | Pfizer, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097817-A9 | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER JAPAN INC (JP) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006103503-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006097817-A1 | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER JAPAN INC. (JP) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-0490703-A1 | Trisubstituted silylalkyl 1,2,4-triazole and imidazole phenyl borane derivatives | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1992-06-17 | — | — | EP | disclosed |
| US-5091377-A | Trisubstituted silylalkyl 1,2,4-triazole and imidazole phenyl borane derivatives | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1992-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | ORAI1 933/4885ORAI2 713/4885ORAI3 558/4885 |
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | OPRL1, CNR1, TRPV1 | ORAI1 275/4885ORAI2 304/4885ORAI3 640/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | ORAI1 951/4885ORAI2 711/4885ORAI3 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.